ZhongShan Hospital, Fudan

Company snapshot

Zhongshan Hospital affiliated to Fudan University is a subsidiary of the National Health and Wellness Commission and a comprehensive teaching hospital affiliated to Fudan University. The hospital opened in 1937 and was one of the earliest large-scale comprehensive hospitals created and managed by the Chinese. It was named after the National Shanghai Medical College and named after Sun Yat-sen, the

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ZhongShan Hospital, Fudan. Not investment advice.

• What is ZhongShan Hospital, Fudan?

  Shanghai Zhongshan Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Interstitial Lung Disease (ILD), Gastrointestinal Disease, Takayasu Arteritis. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) t

• Is ZhongShan Hospital, Fudan publicly traded?

  ZhongShan Hospital, Fudan appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does ZhongShan Hospital, Fudan develop or market?

  We link 8 drug profile(s) where ZhongShan Hospital, Fudan is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/shanghai-zhongshan-hospital#company-drugs.

• What are the latest developments for ZhongShan Hospital, Fudan?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ZhongShan Hospital, Fudan focus on?

  ZhongShan Hospital, Fudan focuses on Interstitial Lung Disease (ILD), Gastrointestinal Disease, Takayasu Arteritis based on our analysis of their pipeline programs and drug development activities.